HSBC Holdings’s Amylyx Pharmaceuticals AMLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$958K Buy
32,920
+18,366
+126% +$487K ﹤0.01% 1963
2026
Q2
$269K Buy
14,554
+3,140
+28% +$48.6K ﹤0.01% 2570
2026
Q1
$157K Buy
+11,414
New +$161K ﹤0.01% 2671
2025
Q4
– Sell
-19,369
Closed -$278K – 2919
2025
Q3
$278K Buy
+19,369
New +$182K ﹤0.01% 2358
2025
Q2
– Sell
-14,419
Closed -$51.4K – 3017
2025
Q1
$51.4K Buy
14,419
+2,853
+25% +$10.2K ﹤0.01% 2901
2024
Q4
$43.3K Sell
11,566
-50,121
-81% -$236K ﹤0.01% 3008
2024
Q3
$197K Sell
61,687
-14,574
-19% -$32.8K ﹤0.01% 2620
2024
Q2
$150K Buy
76,261
+27,954
+58% +$54.2K ﹤0.01% 2644
2024
Q1
$137K Buy
+48,307
New +$632K ﹤0.01% 2774

Other funds holding AMLX

HSBC Holdings's AMLX Position: Q3 2026 in Review

HSBC Holdings increased its Amylyx Pharmaceuticals (AMLX) stake by 126% in Q3 2026, buying an estimated $487K and bringing the position to 32,920 shares worth $958K. The position accounts for ﹤0.01% of the portfolio, ranked #1963.

HSBC Holdings first reported a position in AMLX in Q1 2024 and has held it in 9 quarters since. 230 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.

  • HSBC Holdings held 32,920 shares of Amylyx Pharmaceuticals worth $958K as of Q3 2026.
  • HSBC Holdings bought 18,366 Amylyx Pharmaceuticals shares in Q3 2026, an estimated $487K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of HSBC Holdings's portfolio in Q3 2026, its #1963 holding.
  • HSBC Holdings first reported a position in Amylyx Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • 230 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.

Based on HSBC Holdings's 13F filing for Q3 2026, filed 16 Nov 2026.